source
- Recon: FDA adcomm votes against Capricor’s DMD drug; Cytokinetics gets UK approval, NICE backing for heart drugWelcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.raps · 1d ago↗ source
- Heart Pump Recall: Abiomed Removes Impella CP Sets with SmartAssistSpecific Impella CP Sets are out of specification; use may result in low purge pressure events from the onset of the casefda medwatch · 29d ago↗ source
- REVELUTION-2 Trial Is Evaluating Cardiovascular Risk With Relugolix Plus Abiraterone Acetate in High-Risk Prostate CancerSagar A. Patel, MD, discusses the REVELUTION-2 trial evaluating cardiovascular safety with hormone therapy in prostate cancer.